# Relative Bioavailability Study of HR19042 in Healthy Subjects

> **NCT06922305** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Primary IgA Nephropathy; Autoimmune Hepatitis

## Interventions

- **DRUG:** HR19042 Capsule, Tarpeyo®, Budenofalk®

## Key facts

- **NCT ID:** NCT06922305
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-27
- **Primary completion:** 2024-01-25
- **Final completion:** 2024-01-25
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06922305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06922305, "Relative Bioavailability Study of HR19042 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06922305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*